Institution
Tohoku University
Education•Sendai, Japan•
About: Tohoku University is a education organization based out in Sendai, Japan. It is known for research contribution in the topics: Magnetization & Alloy. The organization has 72116 authors who have published 170791 publications receiving 3941714 citations. The organization is also known as: Tōhoku daigaku.
Topics: Magnetization, Alloy, Catalysis, Population, Magnetic field
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, two 1,2-disilacyclobutenes were prepared by the reaction of tetramethyldisilene with acetylenes, and several reactions of these new 1 2 disilacy clobutenets including oxidation, silylene insertion, iron carbonyl insertion, and addition to acetylene and dienes are reported.
345 citations
••
TL;DR: Grain boundaries can be effectively controlled to produce or enhance their beneficial effects and also to diminish or reduce their detrimental effects on bulk properties in polycrystalline materials as mentioned in this paper, which remains a serious problem of material processing and development.
344 citations
••
TL;DR: In this article, a novel polyether toxin, yessotoxin, was isolated from scallops implicated in diarrhetic shellfish poisoning, and its planar structure was proposed by means of modern NMR techniques.
343 citations
••
TL;DR: The homogeneous conditions and conditions for inhibiting char formation by phenol were elucidated and it was found that mixtures of phenol and lignin become homogeneous at 400-600 degrees C and high water densities of 428-683 kg/m3, corresponding to maximum pressures of 93 MPa.
343 citations
••
TL;DR: CANTOS provides proof of concept evidence in humans that modulation of the IL-6 signalling pathway, at least with canakinumab, associates with reduced cardiovascular event rates, independent of lipid lowering.
Abstract: Aims Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through interleukin-6 (IL-6) signalling, an issue with substantial pathophysiologic consequences and therapeutic implications. Methods and results A total of 4833 stable atherosclerosis patients in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) had IL-6 levels measured before randomization and after treatment with placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months. Participants were followed for up to 5 years (median follow-up 3.7 years). Compared with those allocated to placebo, CANTOS participants receiving canakinumab who achieved on-treatment IL-6 levels below the study median value of 1.65 ng/L experienced a 32% reduction in major adverse cardiovascular events [MACE, multivariable adjusted hazard ratio (HRadj) 0.68, 95% confidence interval (CI) 0.56-0.82; P < 0.0001], a 30% reduction in MACE plus the additional endpoint of hospitalization for unstable angina requiring urgent revascularization (MACE+, HRadj 0.70, 95% CI 0.59-0.84; P < 0.0001), a 52% reduction in cardiovascular mortality (HRadj 0.48, 95% CI 0.34-0.68; P < 0.0001), and a 48% reduction in all-cause mortality (HRadj 0.52, 95% CI 0.40-0.68; P < 0.0001) with prolonged treatment. In contrast, those with on-treatment IL-6 levels equal to or above 1.65 ng/L after taking the first dose of canakinumab had no significant benefit for any of these endpoints. These differential findings based on the magnitude of IL-6 response were seen in analyses alternatively based on tertiles of on-treatment IL-6 levels, and in analyses using a statistical inference approach to estimate the effect of treatment among individuals who would achieve a targeted IL-6 level. Conclusion CANTOS provides proof of concept evidence in humans that modulation of the IL-6 signalling pathway, at least with canakinumab, associates with reduced cardiovascular event rates, independent of lipid lowering. Clinical trial registration ClinicalTrials.gov NCT01327846.
343 citations
Authors
Showing all 72477 results
Name | H-index | Papers | Citations |
---|---|---|---|
John Q. Trojanowski | 226 | 1467 | 213948 |
Aaron R. Folsom | 181 | 1118 | 134044 |
Marc G. Caron | 173 | 674 | 99802 |
Masayuki Yamamoto | 171 | 1576 | 123028 |
Kenji Watanabe | 167 | 2359 | 129337 |
Rodney S. Ruoff | 164 | 666 | 194902 |
Frederik Barkhof | 154 | 1449 | 104982 |
Takashi Taniguchi | 152 | 2141 | 110658 |
Yoshio Bando | 147 | 1234 | 80883 |
Thomas P. Russell | 141 | 1012 | 80055 |
Ali Khademhosseini | 140 | 887 | 76430 |
Marco Colonna | 139 | 512 | 71166 |
David H. Barlow | 133 | 786 | 72730 |
Lin Gu | 130 | 868 | 56157 |
Yoichiro Iwakura | 129 | 705 | 64041 |